The deal size was increased to $200M from $150M and priced below last closing price of $128.60. TD Cowen, Cantor Fitzgerald, Stifel, Mizuho, LifeSci Capital, Oppenheimer, Canaccord and H.C. Wainwright are acting as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $250 from $205 at Mizuho
- Palvella Therapeutics price target raised to $215 from $192 at BTIG
- Robust Phase 3 SELVA Results for QTORIN Rapamycin Drive Confident Buy Rating on PVLA
- Palvella Therapeutics announces $150M proposed public offering of common stock
- Palvella Therapeutics price target raised to $210 from $190 at Truist